Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 3101 - 3200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 3101 | 26617003 |
US |
51 | 2 |
Dermatitis atopic, Respiratory symptom, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 3102 | 26617130 |
US |
47 | 2 |
Behaviour disorder, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3103 | 26617270 |
US |
2 | |
Infection, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3104 | 26617455 |
US |
40 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 3105 | 26617819 |
US |
61 | 2 |
Dermatitis atopic, Product prescribing error, |
||||
DELGOCITINIB, |
||||
| 3106 | 26617883 |
CR |
26 | 1 |
Staphylococcal bacteraemia, Streptococcal bacteraemia, Dermatitis atopic, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 3107 | 26619117 |
US |
63 | |
Dermatitis atopic, Drug ineffective, |
||||
NEMOLIZUMAB-ILTO, TAPINAROF, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, |
||||
| 3108 | 26619140 |
US |
72 | 2 |
Injection site bruising, Arthralgia, Conjunctivitis, Pruritus, Headache, Myalgia, Condition aggravated, Skin exfoliation, Mobility decreased, Swelling, Skin mass, Neurodermatitis, Dermatitis atopic, Flushing, Discomfort, Pain in extremity, |
||||
MELOXICAM, DUPILUMAB, |
||||
| 3109 | 26610252 |
US |
58 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3110 | 26610263 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3111 | 26610298 |
US |
38 | 2 |
Dry skin, Scab, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3112 | 26610335 |
US |
45 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3113 | 26610343 |
US |
9 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3114 | 26610356 |
US |
11 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3115 | 26610360 |
US |
59 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3116 | 26610364 |
US |
47 | 1 |
Dermatitis atopic, Product dose omission issue, Rash, Therapeutic product effect incomplete, |
||||
DUPILUMAB, |
||||
| 3117 | 26610367 |
US |
20 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3118 | 26610368 |
US |
13 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3119 | 26610378 |
US |
43 | 2 |
Swelling, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3120 | 26610391 |
US |
7 | 1 |
Infection, Eczema infantile, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3121 | 26610397 |
US |
71 | 2 |
Dermatitis, Arthralgia, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3122 | 26610399 |
US |
81 | 1 |
Eye disorder, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 3123 | 26610406 |
US |
67 | 2 |
Dermatitis atopic, Rash, Dermatitis allergic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3124 | 26610409 |
US |
14 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 3125 | 26610410 |
US |
2 | 1 |
Dermatitis atopic, Rash erythematous, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 3126 | 26610413 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3127 | 26610415 |
US |
25 | 2 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 3128 | 26610422 |
US |
48 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 3129 | 26611359 |
US |
79 | 1 |
Pneumonia, Influenza, Pruritus, Therapeutic response shortened, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3130 | 26611363 |
US |
1 | |
Dry eye, Dermatitis atopic, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 3131 | 26611418 |
US |
1 | |
Dermatitis atopic, Rash erythematous, Pruritus, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 3132 | 26611427 |
US |
33 | 2 |
Dermatitis atopic, Rash, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3133 | 26611428 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3134 | 26611440 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, BUSPIRONE HYDROCHLORIDE, PROGESTERONE, FISH OIL, MELOXICAM, UPADACITINIB, FISH OIL, |
||||
| 3135 | 26611468 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, AMLODIPINE BESYLATE, AMPHETAMINE, AMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, CHLORTHALIDONE, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, |
||||
| 3136 | 26611473 |
US |
2 | |
Dermatitis atopic, Skin irritation, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 3137 | 26611487 |
US |
2 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3138 | 26611573 |
US |
77 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3139 | 26611605 |
US |
58 | 1 |
Depressed mood, Decreased interest, Depression, Dermatitis atopic, Dermatitis contact, Rash, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, CABOTEGRAVIR, BIMATOPROST, CLONAZEPAM, COLLAGENASE SANTYL, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, DUTASTERIDE, ESTRADIOL CYPIONATE, GABAPENTIN, IRON, LINACLOTIDE, LITHIUM CARBONATE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PROGESTERONE, ROPINIROLE HYDROCHLORIDE, SILDENAFIL CITRATE, SILDENAFIL, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, |
||||
| 3140 | 26611614 |
US |
2 | |
Eye discharge, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3141 | 26611633 |
US |
59 | 2 |
Urticaria, Stress, Rash, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 3142 | 26611639 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3143 | 26611737 |
US |
1 | |
Injection site pain, Dermatitis atopic, |
||||
DUPILUMAB, EPINEPHRINE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 3144 | 26611777 |
US |
18 | 2 |
Dermatitis atopic, Maternal exposure during pregnancy, |
||||
DUPILUMAB, NORGESTIMATE AND ETHINYL ESTRADIOL, |
||||
| 3145 | 26611795 |
US |
15 | 1 |
Dermatitis atopic, Hordeolum, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 3146 | 26611796 |
US |
2 | |
Injection site pain, Dermatitis atopic, |
||||
DUPILUMAB, ROFLUMILAST, |
||||
| 3147 | 26611859 |
US |
48 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3148 | 26612004 |
US |
1 | |
Dermatitis atopic, Device defective, Drug dose omission by device, |
||||
DUPILUMAB, |
||||
| 3149 | 26612007 |
US |
2 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, ALBUTEROL SULFATE, CETIRIZINE HYDROCHLORIDE, |
||||
| 3150 | 26612087 |
US |
11 | 1 |
Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, DUPILUMAB, AMLODIPINE, AMLODIPINE, CRISABOROLE, GUANFACINE, GUANFACINE HYDROCHLORIDE, GAUNFACINE, HYDROCHLOROTHIAZIDE, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, LORATADINE, LORATADINE ORAL, MELATONIN, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, |
||||
| 3151 | 26612090 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3152 | 26612097 |
US |
4 | 2 |
Dermatitis atopic, Product dose omission issue, Rash erythematous, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 3153 | 26612104 |
US |
1 | |
Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 3154 | 26612129 |
US |
69 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3155 | 26612132 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3156 | 26612144 |
US |
32 | 2 |
Alopecia, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3157 | 26612145 |
US |
7 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3158 | 26612146 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3159 | 26612156 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3160 | 26612159 |
US |
33 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3161 | 26612160 |
US |
31 | 2 |
Dermatitis atopic, Stress, |
||||
DUPILUMAB, |
||||
| 3162 | 26612220 |
US |
3 | 2 |
Dermatitis atopic, Erythema, Pruritus, |
||||
DUPILUMAB, |
||||
| 3163 | 26612223 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3164 | 26612329 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3165 | 26612330 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, METHYLPREDNISOLONE, PLECANATIDE, |
||||
| 3166 | 26612341 |
US |
2 | |
Blister, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3167 | 26612615 |
US |
39 | 2 |
Dermatitis atopic, Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3168 | 26612993 |
US |
13 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3169 | 26613070 |
US |
40 | 2 |
Dermatitis atopic, Rash, Erythema, Blister, |
||||
DUPILUMAB, |
||||
| 3170 | 26613075 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3171 | 26613110 |
US |
2 | |
Dermatitis atopic, Rash, Pruritus, |
||||
DUPILUMAB, |
||||
| 3172 | 26613112 |
US |
7 | 2 |
Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 3173 | 26613123 |
US |
2 | |
Pyrexia, Eye pain, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE, CLONAZEPAM, TIRZEPATIDE, HYDROCHLOROTHIAZIDE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, |
||||
| 3174 | 26613160 |
US |
48 | 2 |
Joint noise, Spinal deformity, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3175 | 26613170 |
US |
41 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3176 | 26613175 |
US |
33 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Skin exfoliation, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 3177 | 26613220 |
US |
57 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3178 | 26613234 |
US |
14 | 2 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 3179 | 26613313 |
US |
38 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3180 | 26613328 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3181 | 26613362 |
US |
42 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3182 | 26613398 |
US |
2 | |
Dermatitis atopic, Dry skin, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3183 | 26614871 |
EU |
28 | 1 |
Dermatitis atopic, Pain in extremity, Arthritis, Middle insomnia, Topical steroid withdrawal reaction, Drug ineffective, Therapy cessation, Withdrawal syndrome, Scab, Inflammatory pain, Inflammation, Movement disorder, Steroid dependence, Wound secretion, Seizure, Erythema, Swelling of eyelid, Skin exfoliation, Asthenia, Pruritus, Burning sensation, Mental disorder, Sensitive skin, Eyelid margin crusting, Joint swelling, Swelling, Skin swelling, Peripheral swelling, Loss of personal independence in daily activities, Product prescribing error, Product use in unapproved indication, Off label use, |
||||
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, BETAMETHASONE VALERATE, BETAMETHASONE VALERATE FOAM, DESONIDE, DESONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE, DESONIDE, DESONIDE, DESONIDE, CICLOPIROX OLAMINE, |
||||
| 3184 | 26615863 |
US |
||
Dermatitis atopic, |
||||
RUXOLITINIB, |
||||
| 3185 | 26616194 |
US |
62 | 2 |
Hip arthroplasty, Psoriasis, Rosacea, Cough, Sneezing, Hepatic enzyme increased, Arthralgia, Joint swelling, Musculoskeletal disorder, Papule, Urticaria, Fall, Arthralgia, Dermatitis atopic, |
||||
UPADACITINIB, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, |
||||
| 3186 | 26609171 |
US |
59 | 1 |
Dermatitis atopic, Pruritus, Burning sensation, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3187 | 26609197 |
US |
56 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3188 | 26609310 |
US |
41 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3189 | 26609315 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, Rash erythematous, Erythema, Urticaria, |
||||
DUPILUMAB, |
||||
| 3190 | 26609320 |
US |
23 | 1 |
Dermatitis atopic, Erythema, Product dose omission issue, Dry eye, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 3191 | 26609322 |
US |
2 | |
Dermatitis atopic, Arthralgia, Pain in extremity, Rash, Drug ineffective, Erythema, |
||||
DUPILUMAB, |
||||
| 3192 | 26609343 |
US |
1 | |
Dermatitis atopic, Dermatitis allergic, Erythema, |
||||
DUPILUMAB, DUPILUMAB, RIMEGEPANT SULFATE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PROPRANOLOL HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE, |
||||
| 3193 | 26609358 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3194 | 26609396 |
US |
60 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3195 | 26609402 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3196 | 26609430 |
US |
2 | |
Rash erythematous, Inflammation, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, EPINEPHRINE, ADRENALINUM, |
||||
| 3197 | 26609437 |
US |
28 | 1 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, ALBUTEROL SULFATE AND BUDESONIDE, ALBUTEROL SULFATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, EPINEPHRINE, ADRENALINUM, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISONE, |
||||
| 3198 | 26609440 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3199 | 26609447 |
US |
50 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3200 | 26609450 |
US |
58 | 2 |
Dermatitis atopic, Treatment failure, Incorrect dose administered, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, CALCIUM, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, MONTELUKAST SODIUM, MONTELUKAST, BECLOMETHASONE DIPROPIONATE HFA, SULFAMETHOXAZOLE AND TRIMETHOPRIM, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, UPADACITINIB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30